Outcomes of IDH1/2 mutant AML patients treated with IDH1/2 inhibitors: A single institutional experience.

Constantine Logothetis,Chetasi Talati,Gregoire Calon,Nathan P. Horvat,Virginia O. Volpe,Nicole D. Vincelette,Andrew T. Kuykendall,Onyee Chan,David A. Sallman,Eric Padron,Kendra L. Sweet,Rami S. Komrokji,Ling Zhang,Jeffrey E. Lancet,Seongseok Yun

Outcomes of IDH1/2 mutant AML patients treated with IDH1/2 inhibitors: A single institutional experience.

2021

Constantine Logothetis
Chetasi Talati
Gregoire Calon
Nathan P. Horvat
Virginia O. Volpe
Nicole D. Vincelette
Andrew T. Kuykendall
Onyee Chan
David A. Sallman
Eric Padron
Kendra L. Sweet
Rami S. Komrokji
Ling Zhang
Jeffrey E. Lancet
Seongseok Yun

e19010Background: Recent studies showed that IDH1/2 are frequently mutated in AML and that aberrant 2-HG elevation driven by the mutant IDH1/2 proteins plays a pivotal role in AML development. Subs...

Keywords:

Medicine
Mutant
Cancer research
IDH1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations